The Samsung valuation likely will meet the $4M equity requirement, unfortunately as NP pointed out in the last call that the commercial grade inventory would not be delivered until early 2021.....so this will not be an asset in the balance sheet until received. The $100M commercial grade inventory they expect to have by the end of 2019 sounds great, but because the asset value is cost, IMO will not be enough to get there alone (my estimate is that it will improve the balance sheet between $8-$12M.....which would be an improvement but still short) .....IMO we will need a cash infusion to meet the equity requirement and why I think a license deal is the key to both a $2 share price and enough equity to improve the balance sheet once a milestone payment or two are received.
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.